Literature DB >> 32026776

Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects.

Saleh A Alanazi1, Fars Alanazi1, Nazrul Haq1, Faiyaz Shakeel1, Mohamed M Badran1, Gamaleldin I Harisa1.   

Abstract

The prevalence of liver cancer is increasing over the years and it is the fifth leading cause of mortality worldwide. The intrusive features and burden of low survival rate make it a global health issue in both developing and developed countries. The recommended chemotherapy drugs for patients in the intermediate and advanced stages of various liver cancers yield a low response rate due to the nonspecific nature of drug delivery, thus warranting the search for new therapeutic strategies and potential drug delivery carriers. There are several new drug delivery methods available to ferry the targeted molecules to the specific biological environment. In recent years, the nano assembly of lipoprotein moieties (lipidic nanoparticles) has emerged as a promising and efficiently tailored drug delivery system in liver cancer treatment. This increased precision of nano lipoproteins conjugates in chemotherapeutic targeting offers new avenues for the treatment of liver cancer with high specificity and efficiency. This present review is focused on concisely outlining the knowledge of liver cancer diagnosis, existing treatment strategies, lipoproteins, their preparation, mechanism and their potential application in the treatment of liver cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  HDL; LDL; Liver cancer; anticancerzzm321990drugs; drug delivery systems; ligand-target; lipoproteins; receptor lipidic nanoparticle; therapeutic application

Year:  2020        PMID: 32026776     DOI: 10.2174/1567201817666200206104338

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  2 in total

1.  Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.

Authors:  Yingjie Qi; Guangxuan Liu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

2.  Identification of diffusion weighted imaging would be affected before and after Gd-EOB-DTPA in patients with focal hepatic lesions: an observational study.

Authors:  Hehan Tang; Yuan Yuan; Liping Deng; Yi Wei; Guoyong Chen; Tong Zhang; Lisha Nie; Xiaocheng Wei; Bin Song; Zhenlin Li
Journal:  Ann Transl Med       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.